Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable VANCOUVER, BC, June 24, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus…

Source

Previous articleBook Review: Alexander Shulgin’s The Nature of Drugs
Next articleSilo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family